Globus Medical (NYSE:GMED) Given New $120.00 Price Target at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Globus Medical to $120 (from $115) and kept an outperform rating, implying about a 51.7% upside from the prior close.
• Globus Medical beat Q1 estimates—EPS of $1.12 vs. $0.92 and revenue up 27% year‑over‑year—and set FY2026 guidance of $4.70–$4.80 EPS.
• Despite the strong quarter, shares fell to $79.09; the stock trades at roughly a 20x P/E, with an average analyst target of $106.36 and a consensus rating of "Moderate Buy."

Globus Medical (NYSE:GMED - Get Free Report) had its price objective hoisted by investment analysts at Royal Bank Of Canada from $115.00 to $120.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical device company's stock. Royal Bank Of Canada's target price points to a potential upside of 51.72% from the company's previous close.

Several other analysts have also issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a "buy" rating in a report on Friday, January 9th. Needham & Company LLC boosted their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a report on Friday. Barclays boosted their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Piper Sandler restated an "overweight" rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Finally, TD Cowen upgraded shares of Globus Medical to a "strong-buy" rating in a report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $106.36.

Globus Medical Stock Performance

Shares of NYSE GMED traded down $5.98 during trading on Friday, hitting $79.09. 2,551,746 shares of the company were exchanged, compared to its average volume of 1,233,959. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40. The company has a fifty day moving average price of $89.86 and a 200-day moving average price of $86.65. The firm has a market capitalization of $10.70 billion, a PE ratio of 20.01, a P/E/G ratio of 2.09 and a beta of 1.00.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 EPS. The company's quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts anticipate that Globus Medical will post 4.46 earnings per share for the current fiscal year.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 18.38% of the company's stock.

Hedge Funds Weigh In On Globus Medical

Institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Advisory Services Network LLC acquired a new position in Globus Medical in the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. Larson Financial Group LLC grew its position in Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company's stock valued at $46,000 after acquiring an additional 242 shares in the last quarter. Finally, First Horizon Corp acquired a new position in Globus Medical in the 3rd quarter valued at about $31,000. 95.16% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q1 beat and raised FY26 EPS guide — Q1 EPS of $1.12 topped consensus and revenue rose 27% y/y; company set FY‑2026 EPS guidance to $4.70–4.80 (above consensus). GMED Stock Rises on Q1 Earnings & Revenue Beat
• Positive Sentiment: Analyst support lifted — Needham raised its price target (to $117) and maintained a Buy, signaling continued analyst confidence and added upside vs. the current share price. Benzinga
• Positive Sentiment: Margin expansion and profitability — company reported improved net margin (~18.3%) and higher ROE, underlining operating leverage as revenue scales. GlobeNewswire press release
• Neutral Sentiment: Full call/transcript available — management commentary (earnings call/transcript) can provide detail on procedure volumes, backlog and 2026 cadence; investors should review for execution signals. Earnings Transcript
• Neutral Sentiment: Coverage & analysis — multiple outlets (Zacks, Seeking Alpha, SeattlePI, MarketBeat) ran summaries and metric breakdowns; these refine expectations but don’t change the core beat/guidance story. Zacks Q1 coverage
• Neutral Sentiment: Valuation context — the stock trades at roughly a ~20x P/E with PEG ~2.1; investors will weigh growth vs. multiple when deciding to buy after the run of positive news. MarketBeat profile
• Negative Sentiment: Shares trading lower despite the beat — that divergence suggests short‑term profit taking or broader market/sector weakness; monitor intraday flow and whether weakness extends after the post‑earnings window. Earnings snapshot

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.